Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Cope, Shannon; Donohue, James F; Jansen, Jeroen P; Kraemer, Matthias; Capkun-Niggli, Gorana; Baldwin, Michael; Buckley, Felicity; Ellis, Alexandra; Jones, Paul (2013)
Publisher: BioMed Central
Journal: Respiratory Research
Languages: English
Types: Article
Subjects: Mixed treatment comparison, Pulmonary and Respiratory Medicine, Meta-analysis, Systematic review, Research, COPD, Bronchodilator

Classified by OpenAIRE into

mesheuropmc: respiratory tract diseases
Background: Clinicians are faced with an increasingly difficult choice regarding the optimal bronchodilator for\ud patients with chronic obstructive pulmonary disease (COPD) given the number of new treatments. The objective of this study is to evaluate the comparative efficacy of indacaterol 75/150/300 μg once daily (OD), glycopyrronium\ud bromide 50 μg OD, tiotropium bromide 18 μg/5 μg OD, salmeterol 50 μg twice daily (BID), formoterol 12 μg BID,\ud and placebo for moderate to severe COPD.\ud \ud Methods: Forty randomized controlled trials were combined in a Bayesian network meta-analysis. Outcomes of interest were trough and post-dose forced expiratory volume in 1 second (FEV1), St. George’s Respiratory Questionnaire (SGRQ) score and responders (≥4 points), and Transition Dyspnea Index (TDI) score and responders\ud (≥1 point) at 6 months.\ud \ud Results: Indacaterol was associated with a higher trough FEV1 than other active treatments (difference for indacaterol 150 μg and 300 μg versus placebo: 152 mL (95% credible interval (CrI): 126, 179); 160 mL (95% CrI:\ud 133, 187)) and the greatest improvement in SGRQ score (difference for indacaterol 150 μg and 300 μg versus\ud placebo: -3.9 (95% CrI -5.2, -2.6); -3.6 (95% CrI -4.8, -2.3)). Glycopyrronium and tiotropium 18 μg resulted in the\ud next best estimates for both outcomes with minor differences (difference for glycopyrronium versus tiotropium\ud for trough FEV1 and SGRQ: 18 mL (95% CrI: -16, 51); -0.55 (95% CrI: -2.04, 0.92).\ud \ud Conclusion: In terms of trough FEV1 and SGRQ score indacaterol, glycopyrronium, and tiotropium are expected to\ud be the most effective bronchodilators.\ud

Share - Bookmark

Cite this article